![Arcturus Therapeutics Holdings Inc](/common/images/company/N_ARCT.png)
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of... Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19. Show more
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with...
Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH...
ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF) Phase 1b interim data includes a CF participant...
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024 First four CF patients demonstrated an average improvement of 4% FEV1 after two...
Combines Achillesβ best-in-class AI-driven, tumor-targeting technology with Arcturusβ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire KING OF PRUSSIA, Pa. and SAN DIEGO, May 20...
Arcturus Therapeutics Holdings Inc. (the βCompanyβ, βArcturusβ, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.28 | -13.2525252525 | 24.75 | 24.75 | 20.5201 | 865588 | 22.80927952 | CS |
4 | -20.54 | -48.8931206856 | 42.01 | 42.42 | 20.5201 | 873370 | 27.5103158 | CS |
12 | -10.81 | -33.488228005 | 32.28 | 45 | 20.5201 | 614247 | 29.52518219 | CS |
26 | -9.2 | -29.9967394848 | 30.67 | 45 | 20.5201 | 529474 | 32.22102482 | CS |
52 | -6.8 | -24.0537672444 | 28.27 | 45 | 17.52 | 476314 | 30.10043534 | CS |
156 | -13.08 | -37.8581765557 | 34.55 | 64.9735 | 11.7 | 543609 | 28.95814713 | CS |
260 | 12.02 | 127.195767196 | 9.45 | 129.71 | 8.49 | 583191 | 39.22094537 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.